leisure time -WSS

leisure time

author：focus 2025-09-27 12:54:40 - browse：5817

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In Memoriam: Notable people who died in 2023
Next article： Why failed clinical trials don’t always spell doom for a new drug

knowledge

WSS

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Man killed during FBI raid in connection with threats against Biden, other officials

Man killed during FBI raid in connection with threats against Biden, other officials

A new deal aims to ramp up use of AI in rehab care decisions

A biotech analyst on neuroscience, placebo effect, not over

hotspot

leisure time

focus

Hollywood unions extend contract negotiations for actors

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Alkermes shareholders re

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

DIEP, the 'gold standard' of breast reconstruction, is under threat

Maui's cultural, historic landmarks damaged in the devastating wildfires

Activists slam private health insurers over coverage restrictions

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Cancer drug shortages should be causing more outrage

How Brent Saunders' Allergan experiment failed

focus

EMA weighs against approval for Mirati's lung cancer drug

Emergent cuts jobs, executive role in business shake

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Trump Organization, Michael Cohen agree to settle million

Drastic changes should bring profitability, startup health insurers say

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

knowledge

hotspot

knowledge

entertainment